Table 1 Baseline characteristics of patients enrolled in BCMA/GPRC5D CAR T-cell therapy trial
Baseline Characteristics | N = 9(%) |
|---|---|
Age, years | 64 (48–80) (N/A) |
Male | 4 (44.4) |
Female | 5 (55.6) |
Time of CART treatment after diagnosis, months | 48 (7–160) (N/A) |
Monoclonal globulin IgG | 4 (44.4) |
Monoclonal globulin IgA | 4 (44.4) |
Monoclonal globulinIgD | 1 (11.1) |
Light chain | 1 (11.1) |
Non secretory | 0 (0.0) |
High-risk cytogenetic profile | 6 (66.7) |
High tumor burden | 9 (100.0) |
R-ISS I | 0 (0.0) |
R-ISS II | 2 (22.2) |
R-ISS III | 7 (77.8) |
EMD | 9 (100.0) |
Renal dysfunction | 2 (22.2) |
Previous treatment line > 3 | 8 (88.9) |
Previous BCMA CAR-T treatment | 0 (0.0) |
Previous ASCT treatment | 2 (22.2) |
Therapeutic target BCMA-GPRC5D | 9 (100.0) |